Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ans.18847 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting Ferroptosis in Gastrointestinal Tumors: Interplay of Iron-Dependent Cell Death and Autophagy.
Mol Cell Probes
January 2025
Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Electronic address:
Ferroptosis is a regulated cell death mechanism distinct from apoptosis, autophagy, and necroptosis, marked by iron accumulation and lipid peroxidation. Since its identification in 2012, it has developed into a potential therapeutic target, especially concerning GI disorders like PC, HCC, GC, and CRC. This interest arises from the distinctive role of ferroptosis in the progression of diseases, presenting a new avenue for treatment where existing therapies fall short.
View Article and Find Full Text PDFEfficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast Cancer.
Drugs
January 2025
Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have revolutionized the treatment of hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer, and are now also established agents in the treatment of high-risk and intermediate-risk HR+ early breast cancer. Several strategies regarding CDK4/6i combinations or continuation beyond progression have been successfully evaluated in the metastatic setting, and are considered a standard of care. Mechanism of action of and resistance mechanisms against CDK4/6i in addition to endocrine resistance represent an important research topic, important for the treatment of HR+ breast cancer.
View Article and Find Full Text PDF[Visceral surgery : what's new in 2024].
Rev Med Suisse
January 2025
Service de chirurgie viscérale, Département de chirurgie, Centre hospitalier universitaire vaudois, 1011 Lausanne.
This article highlights some advances in visceral surgery in 2024. In the hepato-pancreato-biliary field, liquid biopsies, immunotherapy, and robotics have revolutionized diagnosis and treatment, while artificial intelligence could enhance planning and operational safety. In endocrine surgery, a more conservative approach is recommended for well-differentiated thyroid cancers.
View Article and Find Full Text PDFChimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy.
J Clin Oncol
January 2025
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Colorectal cancer (CRC) remains a major global health burden, being one of the most prevalent cancers with high mortality rates. Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC.
View Article and Find Full Text PDFTransforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.
Int J Clin Oncol
January 2025
Translational Research Support Section, National Cancer Center Hospital East, Chiba, Japan.
Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!